Skip to main content
Granules India Ltd. logo

Granules India Ltd. — Investor Relations & Filings

Ticker · GRANULES ISIN · INE101D01020 LEI · 335800HJF1KE335ASX37 BSE.NS Manufacturing
Open in API
Filings indexed 957 across all filing types
Latest filing 2024-11-13 Call Transcript
Country IN India
Listing BSE.NS GRANULES

About Granules India Ltd.

https://granulesindia.com/

Granules India Ltd. is a vertically integrated manufacturer specializing in Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs), and Finished Dosages (FDs). The organization maintains a significant global presence through the large-scale production of essential molecules, including Paracetamol, Ibuprofen, Metformin, Methocarbamol, and Guaifenesin. Its business model emphasizes a complete value chain approach, from core chemical synthesis to final product packaging, ensuring operational efficiency and supply chain security. The company serves a diverse international clientele across more than 75 countries, utilizing advanced manufacturing facilities that comply with global regulatory standards. Key strengths include high-volume production capabilities, cost leadership, and a focus on delivering consistent quality in high-demand therapeutic areas.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is a detailed transcript of an earnings conference call for Q2 and half year of FY25 for Granules India Limited. It includes management commentary on financial results, operational updates, regulatory inspection outcomes, R&D progress, and Q&A with analysts. The presence of detailed financial figures, discussion of quarterly performance, and forward-looking statements typical of earnings calls confirms this is a Call Transcript (CT). The document is about 15,000 characters long and contains the full text of the call, not just an announcement or summary, so it is not an Earnings Release (ER) or Report Publication Announcement (RPA).
2024-11-13 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release dated November 8, 2024, announcing that Granules India Limited's Unit V facility has received a US FDA Establishment Inspection Report (EIR) with a 'No Action Indicated' status following an FDA inspection. The content focuses on regulatory compliance and inspection results rather than financial data or detailed report content. It is a public announcement intended for dissemination to stock exchanges and investors. The document is about regulatory inspection results and does not contain financial statements, management discussion, or detailed report data. It is not a full annual or quarterly report, nor a certification or voting result. Therefore, it fits best as a Regulatory Filing (RNS) since it is a general regulatory announcement that does not fit other specific categories.
2024-11-08 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short notice dated November 7, 2024, addressed to stock exchanges, informing about the schedule of an upcoming Analyst/Investor Meeting on November 12, 2024. It explicitly states that no unpublished price-sensitive information will be shared and refers to the latest Investor Presentation available on the company's website. The document does not contain any financial data, results, or detailed report content. It is essentially an announcement about a meeting event rather than the meeting materials or a financial report itself. Given the short length (1611 characters) and the nature of the content, this fits the category of an Investor Presentation announcement or meeting schedule notice. However, since it is only the schedule notice and not the presentation itself, the best fitting category is Regulatory Filings (RNS) as a general regulatory announcement about the meeting schedule, not the presentation document itself.
2024-11-07 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding the audio recording of the earnings conference call for Q2 and half year of FY25. It references a previous letter about the schedule of the earnings call and provides a link to the recording on the company's website. The document does not contain the transcript or detailed financial data itself, but rather an announcement about the availability of the earnings call recording. The document length is short (1659 characters), and it serves as an announcement rather than the actual earnings release or call transcript. Therefore, it fits best under the category of Call Transcript (CT) as it relates to the earnings conference call, but since it only announces the recording and does not provide the transcript, it is more appropriate to classify it as a Regulatory Filing (RNS) as a general announcement related to earnings call recording availability.
2024-11-06 English
Investor Presentation
Investor Presentation Classification · 95% confidence The document is titled 'Earnings Presentation – Q2FY25' and dated November 6, 2024. It contains detailed quarterly financial data including P&L statements, segment revenue splits, cash flow and ratios, historical performance over quarters and years, and business updates such as FDA inspections and product launches. The content is structured as a presentation with slides and charts, typical of investor presentations. There is no indication that this is a full annual report, audit report, or regulatory filing. The document is not a transcript of a call, nor a proxy or voting announcement. It is a detailed presentation aimed at investors focusing on financials, strategy, and market position for the quarter Q2 FY25. Therefore, the document fits the category of an Investor Presentation (IP). The document length is substantial (15,000 characters), indicating it is the full presentation, not just an announcement of a report.
2024-11-06 English
Press Release
Earnings Release Classification · 95% confidence The document is a press release announcing the financial results for the quarter ended September 30, 2024 (Q2FY25). It contains key financial metrics such as revenue, EBITDA, and PAT, along with commentary from the Chairman & Managing Director. The document is concise (under 5,000 characters) and structured as an initial announcement of quarterly financial results rather than a comprehensive report with detailed financial statements or analysis. Therefore, it fits the definition of an Earnings Release (ER), which is the initial announcement of quarterly/periodical financial results with key highlights only. Q2 2025
2024-11-06 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.